GHRP-2 vs MK-677 (Ibutamoren)
A side-by-side research comparison of GHRP-2 and MK-677 (Ibutamoren) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | GHRP-2 | MK-677 (Ibutamoren) |
|---|---|---|
| Full name | Growth Hormone Releasing Peptide-2 (Pralmorelin) | Ibutamoren Mesylate (MK-677) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Investigational |
| Mechanism | Potent GHSR-1a agonist stimulating GH release and appetite. Also mildly stimulates ACTH/cortisol release. | Acts as ghrelin mimetic at GHS-R1a receptors in hypothalamus and pituitary. Excellent oral bioavailability and 24-hour duration. |
| Molecular weight | 818 Da | 528.7 Da |
| Half-life | 1-2 hours | 24 hours |
| Bioavailability | High (SubQ) | High (oral) |
| Typical dose | 100-300 mcg | 10-25 mg |
| Frequency | 2-3x daily | Once daily |
| Route | Subcutaneous | Oral (capsule/liquid) |
GHRP-2 reported benefits
- Strongest GH release among GHRPs
- Appetite stimulation
- Recovery improvement
- Enhanced sleep
- Muscle preservation
MK-677 (Ibutamoren) reported benefits
- Oral administration
- Sustained 24h GH elevation
- Increased IGF-1
- Improved sleep depth
- Enhanced recovery
- Bone density support
Related comparisons
Research and educational reference only. Not medical advice.